STOCK TITAN

InMed Pharmaceuticals awards Hagen 171,000 options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. reported that Senior Vice President, Finance and Chief Accounting Officer Brett R. Hagen received an award of options covering 171,000 common shares. The options vest 25% on November 9, 2027, with the remainder vesting in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.

Insider Hagen Brett R
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 171,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 171,000 options (Direct)
Holdings Before and After: Stock Option (Right to Buy), 0 to 171,000 options (Direct)
Footnotes (1)
  1. F1. This option represents the right to purchase 171,000 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Options awarded 171,000 options Award to Brett R. Hagen
Exercise price $16 per share Option award
Initial vesting 25% Vests on November 9, 2027, with equal monthly installments thereafter through November 9, 2030, subject to continued service
Option expiration November 9, 2036 Option award
Stock Option (Right to Buy) technical
"the award covering 171,000 common shares"
vesting technical
"will vest as to 25% on November 9, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"an exercise price of $16 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did Brett R. Hagen receive from INM?

Brett R. Hagen received an award of options covering 171,000 common shares.

When do Brett R. Hagen's INM options expire?

The options expire on November 9, 2036 and have an exercise price of $16 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hagen Brett R

(Last)(First)(Middle)
C/O MENTARI THERAPEUTICS, INC.
221 CRESCENT ST., BUILDING 23, SUITE 105

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1611/09/2026A171,000 (1)11/09/2036Common Stock171,000$0171,000D
Explanation of Responses:
1. This option represents the right to purchase 171,000 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks:
Senior Vice President, Finance and Chief Accounting Officer
/s/ Jerad G. Seurer, as attorney-in-fact for Brett Hagen11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading